Status
Patent Status: Granted US 10,806,802 and Pending CA 3,023,706
License Status: Seeking non-exclusive licensees and product development collaborators
Technology/Opportunity
The technology is a novel triple mutant AAV6 capsid with significantly improved transfection, expression and tropism for respiratory epithelium. Also, this capsid has very efficient intramuscular expression of monoclonal antibodies useful for emergency vaccine and prophylactic applications or mAb drug delivery.